Proactive Investors - Run By Investors For Investors

Constellation Healthcare’s true valuation closer to US$400mln, says boss

Paul Parmar, chief executive of Constellation Healthcare Technologies (LON:CHT), says that his company is undervalued and he is a “definite buyer” of the shares at the current price.

He attributes general market volatility to the suppression of the stock and says the true valuation of the company, which provides billing services to doctors in the U.S., is closer to US$400mln than today’s market cap of US$188mln.

Parmar spoke to Proactive after confirming the company’s fourth acquisition since Constellation listed on AIM in December 2014.  An upfront payment of US$28mln has been made for MDRX Medical Billing which could rise to US$30mln depending on MDRX's performance over the next two years.

Meet Sayona Mining Ltd, Lithium Power International Ltd, Elementos, Tyranna Resources and Argent Minerals Ltd at our event, Melbourne, 25 July 2017. Register here »

Register here to be notified of future Constellation Healthcare Technologies, Inc. articles
View full CHT profile View Profile

Constellation Healthcare Technologies, Inc. Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use